Company’s 36-month beta value is 0.48.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for ACRS is 59.91M, and currently, short sellers hold a 5.28% ratio of that floaft. The average trading volume of ACRS on December 27, 2024 was 2.36M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ACRS) stock’s latest price update
Aclaris Therapeutics Inc (NASDAQ: ACRS)’s stock price has gone rise by 0.52 in comparison to its previous close of 2.90, however, the company has experienced a -5.36% decrease in its stock price over the last five trading days. benzinga.com reported 2024-12-23 that HC Wainwright & Co. analyst Raghuram Selvaraju upgraded Aclaris Therapeutics Inc ACRS from Neutral to Buy and a price target of $20. The stock gained after the rerating.
ACRS’s Market Performance
Aclaris Therapeutics Inc (ACRS) has seen a -5.36% fall in stock performance for the week, with a -26.94% decline in the past month and a 147.03% surge in the past quarter. The volatility ratio for the week is 8.31%, and the volatility levels for the past 30 days are at 8.93% for ACRS. The simple moving average for the past 20 days is -14.68% for ACRS’s stock, with a 83.15% simple moving average for the past 200 days.
Analysts’ Opinion of ACRS
Many brokerage firms have already submitted their reports for ACRS stocks, with H.C. Wainwright repeating the rating for ACRS by listing it as a “Buy.” The predicted price for ACRS in the upcoming period, according to H.C. Wainwright is $20 based on the research report published on December 23, 2024 of the current year 2024.
Leerink Partners gave a rating of “Outperform” to ACRS, setting the target price at $7 in the report published on November 19th of the current year.
ACRS Trading at 5.14% from the 50-Day Moving Average
After a stumble in the market that brought ACRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.62% of loss for the given period.
Volatility was left at 8.93%, however, over the last 30 days, the volatility rate increased by 8.31%, as shares sank -19.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +147.03% upper at present.
During the last 5 trading sessions, ACRS fell by -5.36%, which changed the moving average for the period of 200-days by +138.93% in comparison to the 20-day moving average, which settled at $3.42. In addition, Aclaris Therapeutics Inc saw 177.62% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACRS starting from Mehra Anand, who purchase 666,666 shares at the price of $2.25 back on Nov 19 ’24. After this action, Mehra Anand now owns 710,030 shares of Aclaris Therapeutics Inc, valued at $1,499,998 using the latest closing price.
Leonard Braden Michael, the 10% Owner of Aclaris Therapeutics Inc, purchase 206,025 shares at $1.24 during a trade that took place back on Aug 05 ’24, which means that Leonard Braden Michael is holding 14,250,000 shares at $256,357 based on the most recent closing price.
Stock Fundamentals for ACRS
Current profitability levels for the company are sitting at:
- -1.5 for the present operating margin
- 0.54 for the gross margin
The net margin for Aclaris Therapeutics Inc stands at -1.37. The total capital return value is set at -0.25. Equity return is now at value -25.83, with -18.47 for asset returns.
Currently, EBITDA for the company is -117.56 million with net debt to EBITDA at 0.77. When we switch over and look at the enterprise to sales, we see a ratio of 5.93. The receivables turnover for the company is 78.95for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.03.
Conclusion
In a nutshell, Aclaris Therapeutics Inc (ACRS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
